News

• Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)
  10/06/2020 / 13:00 - GlobeNewswire
•  
• Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health
  09/14/2020 / 13:30 - GlobeNewswire
•  
• New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio
  09/11/2020 / 14:01 - GlobeNewswire
•  
• New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS
  09/08/2020 / 13:30 - GlobeNewswire
•  
• FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
  08/07/2020 / 13:30 - GlobeNewswire
•  
• Trump making it harder to fight pandemic - pharma trade group
  08/07/2020 / 01:40 - TeleTrader
•  
• Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
  08/06/2020 / 14:02 - GlobeNewswire
•  
• Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease
  07/24/2020 / 22:06 - GlobeNewswire
•  
• Biogen tops estimates with revenue of $3.7B in Q2
  07/22/2020 / 12:52 - TeleTrader
•  
• Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer
  07/22/2020 / 00:00 - GlobeNewswire
•  
• Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)
  07/21/2020 / 13:30 - GlobeNewswire
•  
• The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
  07/08/2020 / 23:01 - GlobeNewswire
•  
• Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease
  07/08/2020 / 13:30 - GlobeNewswire
•  
• New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment
  06/10/2020 / 13:30 - GlobeNewswire
•  
• Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
  06/04/2020 / 13:30 - GlobeNewswire